Patents by Inventor Yanqing Zhao

Yanqing Zhao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10325415
    Abstract: A virtual model display method, device and system are provided. The method includes: receiving a first identification information list sent by an entity equipment; sending the first identification information list to a server. The first identification information list is used for triggering the server to determine a second identification information list according to the first identification information list. The method also includes receiving the second identification information list fed back by the server. The second identification information list includes identification information in the first identification information list and verified by the server. The method also includes acquiring one or more virtual images corresponding to the identification information in the second identification information list; and assembling the one or more virtual images to obtain a virtual model corresponding to the entity equipment.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: June 18, 2019
    Assignee: TENCENT TECHNOLOGY (SHENZHEN) COMPANY LIMITED
    Inventors: Chuankang Fan, Zhe Zhu, Ming Zhao, Yanqing Jing
  • Patent number: 10075324
    Abstract: A predistortion processing apparatus: an auxiliary feedback module, configured to: extract a nonlinear distortion signal from an analog signal, and input an obtained feedback signal corresponding to the nonlinear distortion signal into an auxiliary model coefficient training module; the auxiliary model coefficient training module, configured to: train an auxiliary coefficient according to the feedback signal and a predistortion signal, and transmit a first auxiliary coefficient obtained through training to a predistortion processing module; a radio frequency signal feedback module, configured to extract a fundamental wave feedback signal; a predistortion model coefficient training module, configured to: train a predistortion coefficient according to the predistortion signal and the fundamental wave feedback signal, and transmit an obtained predistortion coefficient to the predistortion processing module; the predistortion processing module, configured to: perform predistortion processing on an input intermedi
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: September 11, 2018
    Assignee: Huawei Technologies Co., Ltd.
    Inventors: Yanqing Zhao, Chunlei Yu, Tingjian Tian
  • Patent number: 9938240
    Abstract: Provided are compounds of Formula I which are derivatives of 3-Hydroxypyridin-4-ones. The compounds may be used in treatment of a medical condition related to a toxic concentration of iron. The compounds may be used for preparation of a medicament for treatment of a medical condition related to a toxic concentration of iron. The medical condition related to a toxic concentration of iron may be selected from the group consisting of: cancer, pulmonary disease, progressive kidney disease and Friedreich's ataxia.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: April 10, 2018
    Assignee: Apotex Inc.
    Inventors: Tim Fat Tam, Regis Leung-Toung, Yingsheng Wang, Yanqing Zhao, Tao Xin, Birenkumar Shah
  • Patent number: 9768811
    Abstract: Embodiments of the present invention disclose a pre-distortion system, including a pre-distortion circuit, a transmission circuit, a power amplifier, a feedback circuit, and a learning circuit. The pre-distortion circuit acquires an in-band intermodulation distortion model coefficient vector, a cross-band modulation distortion model coefficient vector, and an out-of-band intermodulation distortion model coefficient vector that are learned by the learning circuit according to an output signal of the power amplifier, and performs pre-distortion processing on an input digital intermediate frequency signal. Correspondingly, the embodiments of the present invention further disclose a pre-distortion method, which can eliminate impact caused by out-of-band intermodulation distortion on the power amplifier.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: September 19, 2017
    Assignee: Huawei Technologies Co., Ltd.
    Inventors: Tingjian Tian, Yanqing Zhao, Yunfu Dou
  • Publication number: 20170257251
    Abstract: A predistortion processing apparatus: an auxiliary feedback module, configured to: extract a nonlinear distortion signal from an analog signal, and input an obtained feedback signal corresponding to the nonlinear distortion signal into an auxiliary model coefficient training module; the auxiliary model coefficient training module, configured to: train an auxiliary coefficient according to the feedback signal and a predistortion signal, and transmit a first auxiliary coefficient obtained through training to a predistortion processing module; a radio frequency signal feedback module, configured to extract a fundamental wave feedback signal; a predistortion model coefficient training module, configured to: train a predistortion coefficient according to the predistortion signal and the fundamental wave feedback signal, and transmit an obtained predistortion coefficient to the predistortion processing module; the predistortion processing module, configured to: perform predistortion processing on an input intermedi
    Type: Application
    Filed: May 19, 2017
    Publication date: September 7, 2017
    Inventors: Yanqing Zhao, Chunlei Yu, Tingjian TIAN
  • Publication number: 20170247329
    Abstract: Compounds of Formula I which are derivatives of 3-Hydroxypyridin-4-ones. The compounds may be used in treatment of a medical condition related to a toxic concentration of iron. The compounds may be used for preparation of a medicament for treatment of a medical condition related to a toxic concentration of iron. The medical condition related to a toxic concentration of iron may be selected from the group consisting of: cancer, pulmonary disease, progressive kidney disease and Friedreich's ataxia.
    Type: Application
    Filed: May 12, 2017
    Publication date: August 31, 2017
    Inventors: Tim Fat Tam, Regis Leung-Toung, Yingsheng Wang, Yanqing Zhao, Tao Xin, Birenkumar Shah, Blaise Maria N'Zemba, Jolanta Maria Wodzinska, Maryna Premyslova
  • Publication number: 20170088518
    Abstract: Provided are compounds of Formula I which are derivatives of 3-Hydroxypyridin-4-ones. The compounds may be used in treatment of a medical condition related to a toxic concentration of iron. The compounds may be used for preparation of a medicament for treatment of a medical condition related to a toxic concentration of iron. The medical condition related to a toxic concentration of iron may be selected from the group consisting of: cancer, pulmonary disease, progressive kidney disease and Friedreich's ataxia.
    Type: Application
    Filed: December 8, 2016
    Publication date: March 30, 2017
    Inventors: Tim Fat Tam, Regis Leung-Toung, Yingsheng Wang, Yanqing Zhao, Tao Xin, Birenkumar Shah
  • Publication number: 20170085281
    Abstract: The present application discloses a reconfigurable transmitter and receiver, and methods for reconfiguring the same. A system adaptive control circuit generates a control signal according to frequency band information of an input signal; a system clock circuit generates a system clock; a preprocessing circuit preprocesses a received baseband signal according to the system clock and the control signal, to generate a frequency band signal; a digital intermediate frequency processing circuit processes the frequency band signal according to the system clock and the control signal, to generate a digital intermediate frequency signal; a digital-to-analog conversion circuit processes the digital intermediate frequency signal according to the system clock and the control signal, to generate an analog signal; and an analog transmitting circuit transmits the analog signal.
    Type: Application
    Filed: December 5, 2016
    Publication date: March 23, 2017
    Inventors: Yunfu DOU, Tingjian TIAN, Yanqing ZHAO
  • Publication number: 20170047954
    Abstract: Embodiments of the present invention disclose a pre-distortion system, including a pre-distortion circuit, a transmission circuit, a power amplifier, a feedback circuit, and a learning circuit. The pre-distortion circuit acquires an in-band intermodulation distortion model coefficient vector, a cross-band modulation distortion model coefficient vector, and an out-of-band intermodulation distortion model coefficient vector that are learned by the learning circuit according to an output signal of the power amplifier, and performs pre-distortion processing on an input digital intermediate frequency signal. Correspondingly, the embodiments of the present invention further disclose a pre-distortion method, which can eliminate impact caused by out-of-band intermodulation distortion on the power amplifier.
    Type: Application
    Filed: October 28, 2016
    Publication date: February 16, 2017
    Inventors: Tingjian TIAN, Yanqing ZHAO, Yunfu DOU
  • Patent number: 9550733
    Abstract: Provided are compounds of Formula I which are derivatives of 3-Hydroxypyridin-4-ones. The compounds may be used in treatment of a medical condition related to a toxic concentration of iron. The compounds may be used for preparation of a medicament for treatment of a medical condition related to a toxic concentration of iron. The medical condition related to a toxic concentration of iron may be selected from the group consisting of: cancer, pulmonary disease, progressive kidney disease and Friedreich's ataxia.
    Type: Grant
    Filed: June 10, 2015
    Date of Patent: January 24, 2017
    Assignee: Apotex Technologies Inc.
    Inventors: Tim Fat Tam, Regis Leung-Toung, Yingsheng Wang, Yanqing Zhao, Tao Xin, Birenkumar Shah, Blaise N'Zemba, Jolanta Maria Wodzinska, Maryna Premyslova
  • Publication number: 20160083346
    Abstract: Compounds of Formula I which are derivatives of 3-Hydroxypyridin-4-ones. The compounds may be used in treatment of a medical condition related to a toxic concentration of iron. The compounds may be used for preparation of a medicament for treatment of a medical condition related to a toxic concentration of iron. The medical condition related to a toxic concentration of iron may be selected from the group consisting of: cancer, pulmonary disease, progressive kidney disease and Friedreich's ataxia.
    Type: Application
    Filed: December 1, 2015
    Publication date: March 24, 2016
    Inventors: Tim Fat Tam, Regis Leung-Toung, Yingsheng Wang, Yanqing Zhao, Tao Xin, Birenkumar Shah, Blaise N'Zemba, Jolanta Maria Wodzinska, Maryna Premyslova
  • Publication number: 20150335626
    Abstract: Provided are compounds of Formula I which are derivatives of 3-Hydroxypyridin-4-ones. The compounds may be used in treatment of a medical condition related to a toxic concentration of iron. The compounds may be used for preparation of a medicament for treatment of a medical condition related to a toxic concentration of iron. The medical condition related to a toxic concentration of iron may be selected from the group consisting of: cancer, pulmonary disease, progressive kidney disease and Frederich's Ataxia.
    Type: Application
    Filed: June 10, 2015
    Publication date: November 26, 2015
    Inventors: Tim Fat TAM, Regis LEUNG-TOUNG, Yingsheng WANG, Yanqing ZHAO, Tao XIN, Birenkumar SHAH, Blaise N'ZEMBA, Jolanta Maria WODZINSKA, Maryna PREMYSLOVA
  • Publication number: 20150274665
    Abstract: Provided are compounds of Formula I which are derivatives of 3-Hydroxypyridin-4-ones. The compounds may be used in treatment of a medical condition related to a toxic concentration of iron. The compounds may be used for preparation of a medicament for treatment of a medical condition related to a toxic concentration of iron. The medical condition related to a toxic concentration of iron may be selected from the group consisting of: cancer, pulmonary disease, progressive kidney disease and Frederich's Ataxia.
    Type: Application
    Filed: June 11, 2015
    Publication date: October 1, 2015
    Inventors: Tim Fat TAM, Regis LEUNG-TOUNG, Yingsheng WANG, Yanqing ZHAO, Tao XIN, Birenkumar SHAH, Blaise N'ZEMBA, Jolanta Maria WODZINSKA, Maryna PREMYSLOVA, Jianmin Zhang
  • Publication number: 20150225341
    Abstract: The present invention relates to pharmaceutically acceptable crystalline and amorphous salts of D-isoglutamyl-D-tryptophan as well as processes for their manufacture, pharmaceutical compositions comprising them, and their uses in the preparation of pharmaceutical compositions for the treatment of various conditions and/or diseases. In particular, the present invention relates to D-isoglutamyl-D-tryptophan amorphous potassium salt.
    Type: Application
    Filed: February 10, 2014
    Publication date: August 13, 2015
    Inventors: Tim Fat Tam, Blaise N'Zemba, Regis Leung-Toung, Yingsheng Wang, Yanqing Zhao, Lily YU
  • Patent number: 9073865
    Abstract: Provided are compounds of Formula I which are derivatives of 3-Hydroxypyridin-4-ones. The compounds may be used in treatment of a medical condition related to a toxic concentration of iron. The compounds may be used for preparation of a medicament for treatment of a medical condition related to a toxic concentration of iron. The medical condition related to a toxic concentration of iron may be selected from the group consisting of: cancer, pulmonary disease, progressive kidney disease and Frederich's Ataxia.
    Type: Grant
    Filed: July 5, 2010
    Date of Patent: July 7, 2015
    Assignee: Apotex Technologies Inc.
    Inventors: Tim Fat Tam, Regis Leung-Toung, Yingsheng Wang, Yanqing Zhao, Tao Xin, Birenkumar Shah, Blaise N'Zemba, Jolanta Maria Wodzinska, Maryna Premyslova
  • Publication number: 20150011484
    Abstract: The present invention provides pro-drugs of D-gamma-glutamyl-[D/L]-tryptophan, said pro-drugs are compounds of Formula I or pharmaceutically acceptable salts thereof, wherein G is C1-C8 alkyl or benzyl, T is C1-C8 alkyl or benzyl, and * is a chiral carbon in a (R) or (S) configuration, provided that when * is in the (R) configuration, at least one of G and T is C5-C8 alkyl; and use of compounds of Formula I in a pharmaceutical composition.
    Type: Application
    Filed: March 30, 2012
    Publication date: January 8, 2015
    Applicant: APTOEX TECHNOLOGIES, INC.
    Inventors: Tim Fat Tam, Regis Leung-Toung, Yinsheng Wang, Yanqing Zhao, Tao Xin, Wanren Li, Jolanta Maria Wodzinska, Vrajlal S. Rabadia, Birenkumar Shah, Christopher John Feeney
  • Publication number: 20140343050
    Abstract: Provided are carboxylic ester derivatives of formula (I), methods of preparing them, and methods for using them. These compounds are prodrugs of D-isoglutamyl-[D/L]-tryptophan. The in vitro bioconversion of some of the prodrugs to the parent drug D-isoglutamyl-D-tryptophan (or thymodepressin) was tested in human hepatocytes and in human blood. In vivo pharmacokinetic studies following oral administration of some of the prodrugs to rats are also reported.
    Type: Application
    Filed: March 30, 2012
    Publication date: November 20, 2014
    Applicant: APTOEX TECHNOLOGIES, INC.
    Inventors: Tim Fat Tam, Regis Leung-Toung, Yingsheng Wang, Yanqing Zhao, Tao Xin, Wanren Li, Jolanta Maria Wodzinska, Vrajlal S. Rabadia, Christopher John Feeney
  • Patent number: 8735602
    Abstract: The present invention relates to pharmaceutically acceptable crystalline and amorphous salts of D-isoglutamyl-D-tryptophan as well as processes for their manufacture, pharmaceutical compositions comprising them, and their uses in the preparation of pharmaceutical compositions for the treatment of various conditions and/or diseases. In particular, the present invention relates to D-isoglutamyl-D-tryptophan potassium salt (1:1), D-isoglutamyl-D-tryptophan lithium salt (1:1), D-isoglutamyl-D-tryptophan calcium salt (2:1), D-isoglutamyl-D-tryptophan magnesium salt (2:1), and D-isoglutamyl-D-tryptophan organic ammonium salts (1:1).
    Type: Grant
    Filed: March 19, 2012
    Date of Patent: May 27, 2014
    Assignee: Apotex Technologies inc.
    Inventors: Tim Fat Tam, Blaise N'Zemba, Regis Leung-Toung, Yingsheng Wang, Yanqing Zhao, Lily Yu
  • Patent number: 8673943
    Abstract: The present invention relates to novel derivatives of deferiprone. In particular, the present invention relates to fluorinated derivatives of deferiprone or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising same, processes for the manufacture thereof and their use in the treatment of neurodegenerative diseases caused by the presence of free iron or iron accumulation in neural tissues and in diseases wherein excess iron must be removed or redistributed.
    Type: Grant
    Filed: September 26, 2011
    Date of Patent: March 18, 2014
    Assignee: Apotex Technologies Inc.
    Inventors: Tim Fat Tam, Regis Leung-Toung, Yingsheng Wang, Yanqing Zhao
  • Patent number: 8664262
    Abstract: The present invention relates to crystalline forms of the mono-sodium salt of D-isoglutamyl-D-tryptophan, pharmaceutical compositions comprising them, their use in the treatment of various diseases and conditions, and processes for their preparation. In particular, the present invention relates the crystal modification 1 (polymorphic form F) of the mono-sodium salt of D-isoglutamyl-D-tryptophan.
    Type: Grant
    Filed: June 7, 2012
    Date of Patent: March 4, 2014
    Assignee: Apotex Technologies inc.
    Inventors: Tim Fat Tam, Blaise N'Zemba, Regis Leung-Toung, Yingsheng Wang, Yanqing Zhao, Lily Yu